Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors.
We report the successful use of valproate in a 44-year-old woman with migraine induced by selective serotonin reuptake inhibitors. Valproate should be considered for those patients who develop serious migraine for the first time, or worsening of previous migraine, after the initiation of treatment with selective serotonin reuptake inhibitors and for whom continued treatment with this class of drugs is important.
Delva
N J
NJ
Department of Psychiatry, Queen's University, and the Kingston Psychiatric Hospital, Kingston, Ontario, Canada.
Horgan
S A
SA
Hawken
E R
ER
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D018682:GABA Agents / Q000627:therapeutic use*; D006801:Humans; D008881:Migraine Disorders / Q000139:chemically induced* / Q000517:prevention & control*; D010076:Oxazepam / Q000008:administration & dosage / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline / Q000008:administration & dosage / Q000627:therapeutic use; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D018682:GABA Agents; D010076:Oxazepam; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D014635:Valproic Acid